89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Wouter B. Nagengast, Maarten A. de Korte, Thijs H. Oude Munnink, Hetty Timmer-Bosscha, Wifred F. den Dunnen, Harry Hollema, Johan R. de Jong, Michael R. Jensen, Cornelia Quadt, Carlos Garcia-Echeverria, Guus A.M.S. van Dongen, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Elisabeth G.E. de Vries

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Angiogenesis is a critical step in tumor development, in which vascular endothelial growth factor (VEGF) is a key growth aspect. Heat shock protein 90 (HSP90), a molecular chaperone, is essential for the activity of key proteins involved in VEGF transcription. Currently, no biomarkers to predict the effect of, or monitor, HSP90 inhibition therapy in individual patients exist. (89)Zr-bevacizumab PET provides a noninvasive tool to monitor tumor VEGF levels. The aim of this study was to investigate (89)Zr-bevacizumab PET for early antiangiogenic tumor response evaluation of treatment with the new HSP90 inhibitor NVP-AUY922. In xenografts of A2780 and its cisplatin-resistant CP70 human ovarian cancer subline, (89)Zr-bevacizumab small-animal PET was performed before and after NVP-AUY922 treatment and verified with histologic response and ex vivo tumor VEGF levels. Compared with pretreatment values, 2 wk of NVP-AUY922 treatment decreased (89)Zr-bevacizumab uptake by 44.4% (P = 0.0003) in A2780 xenografts, whereas tumor uptake was not affected in CP70 xenografts. The same pattern was observed in A2780 and CP70 tumor VEGF levels, measured with enzyme-linked immunosorbent assay, and mean vessel density after NVP-AUY922 treatment. These findings coincided with reduction in the proliferation rate, assessed by Ki67 staining, in A2780 tumor tissue only. CONCLUSION: (89)Zr-bevacizumab PET was in line with the antiangiogenic response and direct antitumor effects after NVP-AUY922 treatment, supporting the specificity of (89)Zr-bevacizumab PET as a sensitive technique to monitor the antiangiogenic response of HSP90 inhibition in vivo.

Original languageEnglish
Pages (from-to)761-767
Number of pages7
JournalJournal of Nuclear Medicine
Volume51
Issue number5
DOIs
Publication statusPublished - 1 May 2010

Cite this

Nagengast, W. B., de Korte, M. A., Oude Munnink, T. H., Timmer-Bosscha, H., den Dunnen, W. F., Hollema, H., ... de Vries, E. G. E. (2010). 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. Journal of Nuclear Medicine, 51(5), 761-767. https://doi.org/10.2967/jnumed.109.071043
Nagengast, Wouter B. ; de Korte, Maarten A. ; Oude Munnink, Thijs H. ; Timmer-Bosscha, Hetty ; den Dunnen, Wifred F. ; Hollema, Harry ; de Jong, Johan R. ; Jensen, Michael R. ; Quadt, Cornelia ; Garcia-Echeverria, Carlos ; van Dongen, Guus A.M.S. ; Lub-de Hooge, Marjolijn N. ; Schröder, Carolien P. ; de Vries, Elisabeth G.E. / 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. In: Journal of Nuclear Medicine. 2010 ; Vol. 51, No. 5. pp. 761-767.
@article{1d9fc5b0493143c0b252730ba27b10c4,
title = "89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.",
abstract = "Angiogenesis is a critical step in tumor development, in which vascular endothelial growth factor (VEGF) is a key growth aspect. Heat shock protein 90 (HSP90), a molecular chaperone, is essential for the activity of key proteins involved in VEGF transcription. Currently, no biomarkers to predict the effect of, or monitor, HSP90 inhibition therapy in individual patients exist. (89)Zr-bevacizumab PET provides a noninvasive tool to monitor tumor VEGF levels. The aim of this study was to investigate (89)Zr-bevacizumab PET for early antiangiogenic tumor response evaluation of treatment with the new HSP90 inhibitor NVP-AUY922. In xenografts of A2780 and its cisplatin-resistant CP70 human ovarian cancer subline, (89)Zr-bevacizumab small-animal PET was performed before and after NVP-AUY922 treatment and verified with histologic response and ex vivo tumor VEGF levels. Compared with pretreatment values, 2 wk of NVP-AUY922 treatment decreased (89)Zr-bevacizumab uptake by 44.4{\%} (P = 0.0003) in A2780 xenografts, whereas tumor uptake was not affected in CP70 xenografts. The same pattern was observed in A2780 and CP70 tumor VEGF levels, measured with enzyme-linked immunosorbent assay, and mean vessel density after NVP-AUY922 treatment. These findings coincided with reduction in the proliferation rate, assessed by Ki67 staining, in A2780 tumor tissue only. CONCLUSION: (89)Zr-bevacizumab PET was in line with the antiangiogenic response and direct antitumor effects after NVP-AUY922 treatment, supporting the specificity of (89)Zr-bevacizumab PET as a sensitive technique to monitor the antiangiogenic response of HSP90 inhibition in vivo.",
author = "Nagengast, {Wouter B.} and {de Korte}, {Maarten A.} and {Oude Munnink}, {Thijs H.} and Hetty Timmer-Bosscha and {den Dunnen}, {Wifred F.} and Harry Hollema and {de Jong}, {Johan R.} and Jensen, {Michael R.} and Cornelia Quadt and Carlos Garcia-Echeverria and {van Dongen}, {Guus A.M.S.} and {Lub-de Hooge}, {Marjolijn N.} and Schr{\"o}der, {Carolien P.} and {de Vries}, {Elisabeth G.E.}",
year = "2010",
month = "5",
day = "1",
doi = "10.2967/jnumed.109.071043",
language = "English",
volume = "51",
pages = "761--767",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

Nagengast, WB, de Korte, MA, Oude Munnink, TH, Timmer-Bosscha, H, den Dunnen, WF, Hollema, H, de Jong, JR, Jensen, MR, Quadt, C, Garcia-Echeverria, C, van Dongen, GAMS, Lub-de Hooge, MN, Schröder, CP & de Vries, EGE 2010, '89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.' Journal of Nuclear Medicine, vol. 51, no. 5, pp. 761-767. https://doi.org/10.2967/jnumed.109.071043

89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. / Nagengast, Wouter B.; de Korte, Maarten A.; Oude Munnink, Thijs H.; Timmer-Bosscha, Hetty; den Dunnen, Wifred F.; Hollema, Harry; de Jong, Johan R.; Jensen, Michael R.; Quadt, Cornelia; Garcia-Echeverria, Carlos; van Dongen, Guus A.M.S.; Lub-de Hooge, Marjolijn N.; Schröder, Carolien P.; de Vries, Elisabeth G.E.

In: Journal of Nuclear Medicine, Vol. 51, No. 5, 01.05.2010, p. 761-767.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

AU - Nagengast, Wouter B.

AU - de Korte, Maarten A.

AU - Oude Munnink, Thijs H.

AU - Timmer-Bosscha, Hetty

AU - den Dunnen, Wifred F.

AU - Hollema, Harry

AU - de Jong, Johan R.

AU - Jensen, Michael R.

AU - Quadt, Cornelia

AU - Garcia-Echeverria, Carlos

AU - van Dongen, Guus A.M.S.

AU - Lub-de Hooge, Marjolijn N.

AU - Schröder, Carolien P.

AU - de Vries, Elisabeth G.E.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Angiogenesis is a critical step in tumor development, in which vascular endothelial growth factor (VEGF) is a key growth aspect. Heat shock protein 90 (HSP90), a molecular chaperone, is essential for the activity of key proteins involved in VEGF transcription. Currently, no biomarkers to predict the effect of, or monitor, HSP90 inhibition therapy in individual patients exist. (89)Zr-bevacizumab PET provides a noninvasive tool to monitor tumor VEGF levels. The aim of this study was to investigate (89)Zr-bevacizumab PET for early antiangiogenic tumor response evaluation of treatment with the new HSP90 inhibitor NVP-AUY922. In xenografts of A2780 and its cisplatin-resistant CP70 human ovarian cancer subline, (89)Zr-bevacizumab small-animal PET was performed before and after NVP-AUY922 treatment and verified with histologic response and ex vivo tumor VEGF levels. Compared with pretreatment values, 2 wk of NVP-AUY922 treatment decreased (89)Zr-bevacizumab uptake by 44.4% (P = 0.0003) in A2780 xenografts, whereas tumor uptake was not affected in CP70 xenografts. The same pattern was observed in A2780 and CP70 tumor VEGF levels, measured with enzyme-linked immunosorbent assay, and mean vessel density after NVP-AUY922 treatment. These findings coincided with reduction in the proliferation rate, assessed by Ki67 staining, in A2780 tumor tissue only. CONCLUSION: (89)Zr-bevacizumab PET was in line with the antiangiogenic response and direct antitumor effects after NVP-AUY922 treatment, supporting the specificity of (89)Zr-bevacizumab PET as a sensitive technique to monitor the antiangiogenic response of HSP90 inhibition in vivo.

AB - Angiogenesis is a critical step in tumor development, in which vascular endothelial growth factor (VEGF) is a key growth aspect. Heat shock protein 90 (HSP90), a molecular chaperone, is essential for the activity of key proteins involved in VEGF transcription. Currently, no biomarkers to predict the effect of, or monitor, HSP90 inhibition therapy in individual patients exist. (89)Zr-bevacizumab PET provides a noninvasive tool to monitor tumor VEGF levels. The aim of this study was to investigate (89)Zr-bevacizumab PET for early antiangiogenic tumor response evaluation of treatment with the new HSP90 inhibitor NVP-AUY922. In xenografts of A2780 and its cisplatin-resistant CP70 human ovarian cancer subline, (89)Zr-bevacizumab small-animal PET was performed before and after NVP-AUY922 treatment and verified with histologic response and ex vivo tumor VEGF levels. Compared with pretreatment values, 2 wk of NVP-AUY922 treatment decreased (89)Zr-bevacizumab uptake by 44.4% (P = 0.0003) in A2780 xenografts, whereas tumor uptake was not affected in CP70 xenografts. The same pattern was observed in A2780 and CP70 tumor VEGF levels, measured with enzyme-linked immunosorbent assay, and mean vessel density after NVP-AUY922 treatment. These findings coincided with reduction in the proliferation rate, assessed by Ki67 staining, in A2780 tumor tissue only. CONCLUSION: (89)Zr-bevacizumab PET was in line with the antiangiogenic response and direct antitumor effects after NVP-AUY922 treatment, supporting the specificity of (89)Zr-bevacizumab PET as a sensitive technique to monitor the antiangiogenic response of HSP90 inhibition in vivo.

UR - http://www.scopus.com/inward/record.url?scp=77952302437&partnerID=8YFLogxK

U2 - 10.2967/jnumed.109.071043

DO - 10.2967/jnumed.109.071043

M3 - Article

VL - 51

SP - 761

EP - 767

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -

Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. Journal of Nuclear Medicine. 2010 May 1;51(5):761-767. https://doi.org/10.2967/jnumed.109.071043